The first anti-tumor cell product was registered in Belarus

The first antitumor cell product based on killer cells has been registered in Belarus. This was reported by the publication "Medical Bulletin" on January 3.

"Cellular immunotherapy is currently actively used in clinical practice, in particular in the treatment of cancer. This approach is complementary to traditional methods of treatment, allows to reduce the toxic effect of chemopreparations and increase the effectiveness of the therapy. <...> Recently in our country was first registered antitumor biomedical cell product based on human natural killer cells", - stated in the material.

It is specified that the technology is developed by specialists of the Republican Scientific and Practical Center for Children's Oncology, Hematology and Immunology.

Natural killer (NK) cells are a population of lymphocytes of the innate link of immunity, taking an active part in the formation of antitumor and antiviral immune response.

"Human natural killer cells are used in the complex therapy of patients with acute myeloid leukemia, relapsed and resistant forms of acute leukemia," the website adds.

Now the specialists of the Center are discussing the possibility of using EK cells in other oncological diseases.

Spot-on: melanoma vaccine to be tested on patients in fall 2025

What is the principle of its work and how promising is the personalized approach

Earlier, on November 25, 2024, Russian President Vladimir Putin called the introduction of a vaccine against cancer a breakthrough. Then, at a meeting with the Russian leader, the head of the Federal Medical and Biological Agency (FMBA) Veronika Skvortsova told him about the agency's innovative developments in biotechnology, including oncovaccines.

Later, on December 14, 2024, Andrey Kaprin, chief freelance oncologist at the Health Ministry, said that the cancer vaccine will be free for all Russian citizens. In addition, he noted that oncovaccine has shown high efficiency in preclinical trials. Later that month, it was reported that the selection of candidates for participation in clinical trials of the oncovaccine under development had begun.

At the same time, Russian Health Minister Mikhail Murashko said that there was a request for the Russian oncovaccine from other countries.